Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons.
This study analyzed the effects of acute systemic treatment with buthionine sulfoximine (BSO), a synthesis inhibitor of the antioxidant reduced glutathione (GSH), on dopaminergic neurons of the murine nigrostriatal pathway. Part 1 of the study established a dose-response curve and the temporal pattern of GSH loss and recovery in the substantia nigra and striatum following acute BSO treatment. Part 2 of the study determined the effect of acute BSO treatment on the morphology and biochemistry of nigrostriatal neurons. We found that decreases in GSH levels had profound morphological effects, including decreased catecholamine fluorescence per cell, increased levels of lipid peroxidation and lipofuscin accumulation, and increased numbers of dystrophic axons in dopaminergic neurons of the nigrostriatal pathway. However, no measurable effects were observed in biochemical levels of either dopamine or its metabolites. These changes mimic those that have been reported to occur in the nigrostriatal system of rodents with advancing age. Our data suggest that reduction of GSH via BSO treatment results in the same types of nigrostriatal degenerative effects that occur during the aging process and consequently is a good model system for examining the role of GSH in protecting this area of the brain against the harmful effects of age-related oxidative stress.
Andersen
J K
JK
Division of Neurogerontology, Andrus Gerontology Center, University of Southern California, Los Angeles 90089-0191, USA.
Mo
J Q
JQ
Hom
D G
DG
Lee
F Y
FY
Harnish
P
P
Hamill
R W
RW
McNeill
T H
TH
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000375:Aging / Q000502:physiology*; D000818:Animals; D000975:Antioxidants; D019328:Buthionine Sulfoximine / Q000494:pharmacology*; D003342:Corpus Striatum / Q000254:growth & development / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005978:Glutathione / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D013378:Substantia Nigra / Q000254:growth & development / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D000975:Antioxidants; D015102:3,4-Dihydroxyphenylacetic Acid; D008315:Malondialdehyde; D019328:Buthionine Sulfoximine; D014446:Tyrosine 3-Monooxygenase; D005978:Glutathione; D004298:Dopamine; D006719:Homovanillic Acid